On 2026-09-30, the clinical trial status for a study involving degarelix was updated to active, not recruiting. The trial, registered as NCT04989946, is titled "Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer." It is listed as a Phase 1/Phase 2 study.
The trial evaluates androgen deprivation therapy, which includes degarelix, in combination with or without pTVG-AR and with or without T-cell checkpoint blockade. The study population consists of patients newly diagnosed with high-risk prostate cancer.
The current status indicates the trial is no longer enrolling new participants but remains ongoing for those already involved. No results or outcome data have been reported as part of this update. Degarelix is an approved compound used in this trial as part of the androgen deprivation therapy regimen.
Readers seeking more background on degarelix can consult the compound overview for additional context.